Sanofi - ADR
SNY
Market Cap$123.84B
Close$
Earnings Call Q3 2024
October 25, 2024 - AI Summary
**Strong Sales Performance**: Sanofi reported Q3 2024 sales of EUR 13.4 billion, representing a 16% increase in constant currency (CER) and an estimated 11% increase excluding phasing benefits. This indicates a robust underlying growth across their diverse portfolio, particularly driven by Dupixent's strong volume growth.
**Dupixent Growth and Market Expansion**: Dupixent generated sales of almost EUR 3.5 billion for the quarter and is expected to reach around EUR 13 billion for the full year 2024. Recent approvals for COPD in major markets (US and China) are set to enhance its growth trajectory, and strong demand is anticipated due to unmet needs in respiratory conditions.
**Vaccines and Newly Launched Products**: The Vaccines business grew by 26%, benefiting from early season flu sales and Beyfortus's rollout, which is projected to achieve around EUR 1.5 billion in sales for 2024. Newly launched medicines collectively generated substantial revenue, indicating a successful launch strategy that positions Sanofi well for future growth.
Exclusive for Stockcircle Pro members
Sign up
$84.37
62.3% upside
Current Fair Value
62.3% upsideUndervalued by 62.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $123.84 Billion |
|---|---|
| Enterprise Value | $139.20 Billion |
| Dividend Yield | $2.19782 (3.82931052041959%) |
| Earnings per Share | $2.16 |
| Beta | 0.45 |
| Outstanding Shares | 2,506,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 27.3 |
|---|---|
| PEG | 237.73 |
| Price to Sales | 1.93 |
| Price to Book Ratio | 1.79 |
| Enterprise Value to Revenue | 2.01 |
| Enterprise Value to EBIT | 9.01 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sanofi
CEO: Paul Hudson Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...